Table 1. Demographics of the validation cohort.
| LS HLA-DR3+ (n = 10) | Non-LS HLA-DR3+ (n = 11) | LS HLA-DR3− (n = 9) | Non-LS HLA-DR3− (n = 12) | BeS HLA-DR3+ (n = 10) | |
|---|---|---|---|---|---|
| Sex (M/F) | 8/2 | 9/3 | 7/2 | 7/5 | 7/3 |
| Age (yr) | 37 (33–44) | 46 (39–55) | 45 (36–55) | 40 (34–46) | 57 (51–64) |
| Chest radiographical stage a | N/A | ||||
| 0 | 0 | 0 | 1 | 0 | |
| I | 5 | 5 | 5 | 6 | |
| II | 5 | 3 | 2 | 3 | |
| III | 0 | 2 | 0 | 2 | |
| IV | 0 | 0 | 0 | 0 | |
| Smoking status | |||||
| Non | 6 | 9 | 6 | 8 | 3 |
| Former | 3 | 1 | 1 | 1 | 6 |
| Current | 1 | 1 | 2 | 3 | 1 |
| BALF cell concentration (106 cells/liter) | 177 (144–329) | 201 (157–341) | 128 (97–282) | 153 (108–208) | 22 (19–29) |
| % BALF macrophages | 68 (42–87) | 75 (60–78) | 71 (55–83) | 77 (60–82) | 93 (87–96) |
| % BALF lymphocytes | 30 (12–50) | 21 (18–38) | 20 (14–36) | 19 (13–37) | 5.6 (2.8–11) |
| % BALF neutrophils | 1.0 (0.8–1.6) | 1.3 (0.3–1.6) | 1.6 (0.8–3.3) | 1.4 (0.6–2.6) | 0.9 (0.2–1.5) |
| BAL CD4/CD8 ratio | 8 (2–14) | 3.5 (2.9–9.3) | 6.3 (3.3–15.3) | 7.8 (3–12.5) | N/A |
| % TRAV12-1/TRBV2–expressing BAL CD4+ T cells | 6.8 (4.5–10) | 3.4 (1.4–4.7) | 0.1 (0.1–0.1) | 0.1 (0.1–0.2) | N/A |
Data are counts or median (25th–75th percentile). BALF, BAL fluid; N/A, not available.
a
Chest radiography staging as follows: stage 0 = normal chest radiography, stage I = enlarged lymph nodes, stage II = enlarged lymph nodes with parenchymal infiltrates, stage III = parenchymal infiltrates without enlarged lymph nodes, and stage IV = signs of pulmonary fibrosis.